AVTX vs DD · P/E 0.0, rev $441.0K vs P/E 127, rev $12.39B
Avalo Therapeutics Inc (AVTX) versus Dupont De Nemours Inc (DD) — a side-by-side from cached financials, not a winner call.
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
Dupont De Nemours Inc (DD) is a specialty chemicals company listed on US.
Latest reported AVTX revenue for 2024-12-31 was $441.0K. Net income was -$35.1M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.
Latest reported DD revenue for 2024-12-31 was $12.39B. Net income was $738.0M. Revenue was up 2.6% from 2023-12-31 to 2024-12-31. DD currently screens at market cap $19.61B and trailing P/E 127.4.
AVTX currently screens at market cap $51.5M and trailing P/E 0.0. DD currently screens at market cap $19.61B and trailing P/E 127.4.
Not investment advice. Open the AVTX and DD stock pages for the full models.
Not investment advice.